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Abstract 
Recent next-generation-sequencing studies demonstrate that multiple pathways are 
often deregulated in advanced and metastatic prostate cancer (PC). In a recent 
issue of The Journal of Pathology, an elegant study by Jefferies et al used in vivo 
modelling to demonstrate how activation of the PI3K, WNT and MAPK pathway 
converges on mTORC1 signalling to drive aggressive disease. The study also 
highlights that approaches to target advanced PC require intelligent combination of 
agents to target single/multiple signalling pathways in combination with androgen 
receptor (AR) blockade. 
This article is protected by copyright. All rights reserved.
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1002/path.5029 
  
A
cc
ep
te
d 
A
rti
cl
e
In a recent issue of the Journal of Pathology, Jefferies et al [1] investigated the 
impact of deregulated MAPK and WNT pathway activation, on a background of 
PTEN loss in a compound murine model of prostate cancer (PC). The murine 
Probasin (Pb) Cre-LoxP model of PC, driven by Pten (Ptenfl/fl) loss is one of the most 
widely studied models of this disease process in vivo [2]. This model however is slow 
growing, with tumour latency approaching 12 months and rarely metastasises 
without co-operating mutations [3].   
Using both tissue microarrays and in silico analyses Jefferies et al demonstrated that 
concurrent WNT, PI3K, and MAPK pathway was associated with advanced PC, 
correlating with p-S6 kinase expression, a downstream marker of the mTORC1 
pathway [1] (Figure 1). To model this in vivo, they next went on generate a genetic 
model with activation of all three pathways (Catnb+/lox(ex3Ptenfl/flK-Ras+/V12). This 
model had significantly earlier morbidity and mortality (median survival 96 days) 
compared to the single and double mutants [1]. Interestingly a proportion of the 
double mutants (10% of Catnb +/lox(ex3)Ptenfl/fl and 60% of Pten fl/flK-Ras+/V12) 
demonstrated retroperitoneal lymph node metastasis, whilst the triple mutants did 
not display any evidence of metastatic disease, presumably due to the rapid 
progression of the primary tumour in this model [1].   
The triple mutant mice demonstrated activation of WNT (nuclear -catenin), PI3K 
(pAKTThr308) and focal MAPK staining (p-ERK1/2). The ribosomal protein S6 (p-S6240-
244), a marker of mTORC1 pathway activation, was only significantly elevated in the 
triple mutants versus the double mutants, suggesting suppression of negative 
feedback loops controlling mTORC1 in the double mutants [1]. 
In humans, inhibitors of the mTOR pathway, such as rapamycin or everolimus, have 
demonstrated minimal effect in Phase I/II clinical trials on either Prostate Specific 
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Antigen (PSA) levels or clinical progression when used as single agents [4, 5]. This 
intrinsic resistant to mTORC1 inhibitors has been suggested to  be due to MAPK 
activation through a PI3K-dependent feedback loop [6], and as reviewed by Jefferies 
et al multiple preclinical studies have demonstrated the promise of combined 
PI3K/mTOR inhibition [1]. 
This study also reinforces the important role that WNT signalling plays in PC. Recent 
next-generation-sequencing (NGS) studies of WNT signalling in PC have shown that 
APC is one of the most significantly mutated genes in lethal and heavily treated 
tumours [7]. Sequencing of bone or soft tissue metastasis from 150 patients with 
castrate resistant PC (CRPC) demonstrated mutation of the WNT signalling pathway 
in 18% of cases [8]. The WNT cascade can act as a master regulator by integrating 
signals from PI3K/mTOR, MAPK and AR pathways: 
 WNT-dependent inhibition of GSK-3 to stimulate mTORC1 via TSC1/2 axis 
[9] 
 Transcription of AR through TCF/LEF1 (Reviewed in [10]) 
 c-Myc transcription and activation of MAPK signalling [11] 
 Inhibition of MAPK driven senescence [12]   
Therefore, WNT signalling has become an attractive pathway to target in CRPC, 
particularly given its role in advanced disease, where multiple pathways are active 
concurrently. Although a variety of agents exist, from monoclonal antibodies to small 
molecule inhibitors, few have made it to clinical trials [13, 14].   
The study by Jefferies et al highlights how advanced PC is driven by numerous 
pathways, often with different levels of regulation and multiple feedback loops [1].  
NGS of patient’s primary prostate tumours and metastasis provides the opportunity 
to identify which pathways are likely to be activated in both treatment naive and pre-
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treated lesions, allows patients to be commenced on appropriate therapies, whether 
it be with PI3K, WNT and/or MAPK inhibitors in combination with AR inhibition. 
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Figure 1: Interaction of PI3K, MAPK and WNT signalling pathways drives PC 
through mTORC1 signalling  
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